

BUILDING BIOTECH COMPANIES AND STRENGTHENING THE ECOSYSTEM – THE RADFORSK APPROACH

Anders Tuv, Investment Director

RADFORSK IN BRIEF

- Early stage Evergreen Fund dedicated to oncology
- Involved in 20+ start-ups and 8 IPOs
- Former technology transfer office, TTO, for The Norwegian Radium Hospital 1986-2007
- Independent foundation no owners
- Profits used to strengthen cancer research (M\$ 24)
 and to invest in and develop new biotech companies
- Ecosystem builder





WE COMMERCIALIZE CANCER RESEARCH

INVEST AND DEVELOP BIOTECHS




























STRENGTHEN THE BIOTECH ECOSYSTEM





FOCUS ON THE TRANSITION FROM AN ACADEMIC SETTING TO INDUSTRIALISED PRODUCT DEVELOPMENT



ECOSYSTEM PROJECTS STRENGHTENS THE DEALFLOW AND SUPPORTS PRODUCT DEVELOPMENT



OUR PORTFOLIO COMPANIES

-FROM NORWGIAN CANCER RESEARCH TO PRODUCTS ON THE GLOBAL MARKET





















NucliGen






ECOSYSTEM COVERING DEVELOPMENT FROM DISCOVERY TO CLINIC



HOLISTIC APPROACH - MULTIPLE BENEFIT STREAMS



CULTURE AND MINDSET - KEY SUCCESS FACTORS

VISIONARY...



But we have never seen the box...

... EXECUTION ORIENTED

Don't be afraid to fail Be afraid not to try.....

LET'S JOIN FORCES TO STRENGTHEN AND INNOVATE PHARMA/BIOTECH/ACADEMIA COLLABORATIONS

- Science and emerging technologies progress at a lightning speed
- The number and complexity of the innovation enabling factors are increasing
- We need to leverage the fast increasing knowledge and capabilities across academia, biotech, pharma and also across-industry (e.g due to enabling technologies)
- Norway has an untapped science and talent base
- Let's joint forces and innovate collaboration models to develop tomorrow's breakthrough therapies





